

---

# Nutrizym<sup>®</sup>

---

## unique two-stage replacement or supplemental therapy in pancreatic insufficiency

*Extensive clinical evidence\* indicates that Nutrizym is significantly more effective than its competitors in improving fat absorption and protein digestion, and in reducing faecal weight.*

Each Nutrizym tablet has an enteric-coated pancreatic core and a shell of bromelains – proteolytic enzymes of the pineapple – which are active within the pH range of pH3 and pH8 (even pH2 for short periods) and therefore act without loss of enzymatic effectiveness at the low pH found in the stomach.

Following ingestion of the tablet, the bromelains are liberated in the stomach, where proteolytic action is required, and pancreatin is released in the duodenum. Additionally, the bromelains aid digestion in the small intestine where they develop their full proteolytic effect.

Nutrizym is indicated in: pancreatic deficiency states including post-gastrectomy malabsorption, fibrocytic and gastro-intestinal disorders resulting in steatorrhoea.

Nutrizym: each tablet contains Bromelains 50mg. Pancreatin \*\* 4 x N.F. 400mg, and Ox bile 30mg.

\*\* activity equivalent to four times pancreatin B.P.

Dosage: 1 tablet to be taken with meals. Further tablets may be taken according to the degree of pancreatic exocrine insufficiency.

*Full information on request*

---


## **E. Merck Limited, Wokingham, Berks.**

---

\*Brit.med.J., 1970, 4, 21    Medical Digest, 1972, 17, 54    Gastroenterologie 1969, 7, 314.

---

The graph below compares mortality rates due to faecal peritonitis, era by era. It is not pedantically accurate because its sources differ. But the point is fairly made.



Why inaccurate? Because column 4 refers to 23 cases of faecal peritonitis which were treated successfully with Noxyflex. But the \*3 deaths which occurred were due to causes other than peritonitis - as post-mortem revealed. **The mortality rate due to peritonitis can therefore be regarded as zero.**


\* The whole graph, and the causes of the deaths referred to are the subject of the new Noxyflex folder "Why three deaths?" You will receive at least one copy!

**When bacterial contamination  
of the peritoneum is  
diagnosed or suspected:**

**Noxyflex**  
**Geistlich Chester**

2.5G. Noxytiolin and 10 mgm. Amethocaine HCl

**There is  
only one  
absorbable  
suture**





**ETHICON**  
**Surgical Gut**


**The Natural Absorbable you can depend on**

**ETHICON**, LTD. P.O. BOX 408, BANKHEAD AVENUE, EDINBURGH EH11 4HE, SCOTLAND


•Trademark © ETHICON Ltd 1972



**KEY MED**  
the specialist  
service for  
endoscopy  
equipment



Now with the assistance of microscopy, the Olympians of MBL can make the CF-SB, the CF-MB and the CF-DB, and they can now do a much more sophisticated sort of microscopy, called confocal microscopy. This was first demonstrated by Marvin Chalfant and his team at the University of Washington in 1980. In the past, the only microscope that could give a three-dimensional view of a cell was the electron microscope.



New unique the Olympus GIF-D gastrointestinal  
fiberscope, forward viewing, four way angling tip,  
variable focus, automatic exposure photography.  
Working length 1,050 mm

also available  
INTRAGASTRIC CAMERAS  
Full range with or without fiberoptic viewing


## FIBEROPTIC ENDOSCOPUS

- Gastro-intestinal fiberscope
- Oesophago fiberscope
- Broncho fiberscope
- Colono fiberscope
- Kidney fiberscope
- Naso-pharyngeal fiberscope
- Duodeno fiberscope
- Gastro fiberscope
- Vocal Cords fiberscope
- Sigmoid fiberscope
- Choledcho fiberscope

**OLYMPUS** - world leaders in fiberoptic endoscopy.

**KEY MED** specialised medical equipment limited

Maitland House, Warrior Square, Southend-on-Sea SS1 2JY. Telephone: 0702 610381. Telegrams: KEYMED.



# GEFARNIL


**the systemic treatment  
for peptic ulcers**

Gefarnil is unique. Its action is systemic. Gefarnil treats peptic ulcer by acting on the ulcer via the blood stream. Its action is quite specific. By repairing the tissue damage of gastric and duodenal ulceration, Gefarnil heals the ulcer.



Gefarnil is gefarnate in capsules of 50 mg. Gefarnil is manufactured under licence from Istituto de Angeli SpA, Milan, Italy by The Crookes Laboratories Ltd., Basingstoke, Hants, from whom full information is available.

# ARCHIVES FRANÇAISES DES MALADIES DE L'APPAREIL DIGESTIF



**The most important French  
periodical on the subject**

*Organe Officiel de la Société  
Nationale Française de Gastro-  
Entérologie et de ses filiales*

Publishing all articles concerning the work of physicians, surgeons, electro-radiologists and biologists which are relevant to Gastro-enterology.

Starting in 1968, the "Archives Françaises des maladies de l'appareil digestif" — publish four numbers a year entitled "Biologie et Gastroentérologie" devoted to reports on experimental work in gastro-enterology carried out in the new research units of the various French University Hospital Centres.

These articles are original works, clinical, radiological, biological and anatomy-pathological papers (with illustrations and bibliography).

The articles are written in French and followed by a summary in French and English.

The Archives also publish summaries of the Proceedings of the Societies of which they are the

official organ, the texts of conferences or communications which are presented to them, Proceedings of Congresses or Colloquia, book and journal reviews.

The Archives publish announcements of national and international meetings on all subjects concerned with Gastro-enterology.

## SOME ARTICLES RECENTLY PUBLISHED

Erosive gastritis ulcerations and acute gastro-duodenal as source of upper gastrointestinal bleeding in liver cirrhosis, by G. B. J. GLASS and J. KHODADOOST

Lymphocyte transformation to aspirin in patients with 'hemorrhagic gastritis' after oral administration of the drug, by Mm. M. DUFFAUT, P. COLOMBIES, F. GOULLEY and A. RIBET

Primary villous atrophy. Dystrophic lesions of mesenteric lymph nodes. Splenic atrophy. *One case*, by M. R. COLIN, J. HEMET and Y. GEFFROY

Quantitation of alpha-fœtoprotéine (AFP) in primary carcinoma of the liver by Mm. H. HIXSCH-MARIE and C. HUGUET

Primary non-specific mesenteric lymphadenitis in adults. *220 cases*, by Mm. E. Gutzu, B. OGHINA, L. LAUSCH, R. MACARIE and V. TIMOFTE

Multiple lymphomatous polyposis of the rectocolon, by Mm. J.-P. WEILL, Cl. MONATH, J.-M. FARCOT, Mme M. WEILL-BOUSSON and M. J. WARTER


Disordered cholesterol metabolism in digestive pathology. *Second part*, by Mm. J. RAUTUREAU, Th. COSTE and M. RAUTUREAU.

*Subscription (12 numbers) 1972. France F.175. Other countries F.235.*

*Specimen copy available on application to:*

**MASSON & CIE** — Editeurs. 120 Boulevard Saint Germain, **75280 Paris Codex 06**

# The easiest-handling ligature reel ever devised



## **LIGAPAK\*** **Dispenser Reel**

The new LIGAPAK dispenser assures precise ligature control saving both valuable preparation time, and waste of material.

Sterile, ready for use, the material is additionally colour coded by both type and gauge.

**ETHICON**, LTD.  
Scotland

# There is no chemical or clinical equivalent to Carbenoxolone.

A decade of clinical success and biochemical research distinguishes carbenoxolone sodium from liquorice. Carbenoxolone sodium, the single active principle of BIOGASTRONE and DUOGASTRONE, is not a mere extract of liquorice. It is a unique drug, behaving in many ways quite differently from the parent glycoside from which it was first synthesised.

There is abundant evidence, clinical, radiological and endoscopic, that carbenoxolone accelerates the healing of both gastric and duodenal ulcers.

No liquorice extract can show any comparable weight of proof.



Berk Pharmaceuticals Limited  
Godalming & Shalford, Surrey.

## BIOGASTRONE®

Carbenoxolone sodium tablets for gastric ulcer.

## DUOGASTRONE®

Carbenoxolone sodium capsules for duodenal ulcer.



The Queen's Award to Industry 1972 to Biorex  
Laboratories Limited for Technological Innovation  
in the development and production of the drug  
Carbenoxolone Sodium for the treatment of ulcers.

## Pacemakers in the therapy of peptic ulcers

Made under licence from Biorex Laboratories London British Patent numbers 843133, 1093286

© Registered Trade Mark

J.4210



# duphalac<sup>®</sup> in lactulose liver failure

*Duphalac (lactulose) is now well established as a valuable agent in the treatment of portal-systemic encephalopathy. A recent review in Gut\* describes its role in these terms.*

"Lactulose is a useful addition to the existing treatment of cirrhotic patients with neuropsychiatric disorders. Most patients respond particularly those with mild and relatively stable symptoms; such patients may receive lactulose indefinitely, and enjoy improved tolerance of dietary protein . . .

. . . lactulose is free from significant side effects, and therefore falls into place as a valuable alternative to antibiotics when prolonged therapy is required". \*Gut, 1970, 11: 1043-1048

***The following work on Duphalac in portal systemic encephalopathy has been published:***

Treatment of chronic portal-systemic encephalopathy with lactulose *Lancet*, 1966, 1: 890-892

Portal-systemic encephalopathy treated with lactulose (letter) *Lancet*, 1966, 2: 281

Treatment of hepatic system encephalopathy with lactulose *Medical Journal of Australia*, 1968, 2: 160-163

Treatment of portacaval encephalopathy by lactulose *Presse medicale*, 1968, 76: 1675-1676

Cirrhosis, hyperammonaemia and lactulose *Tijdschrift voor Gastro-Enterologie*, 1968, 11: 123-139

Lactulose in the treatment of chronic portal-systemic encephalopathy: a double-blind clinical trial *New England Journal of Medicine*, 1969, 281: 408-412

Long-term treatment of portal-systemic encephalopathy with lactulose *Australasian Annals of Medicine*, 1969, 18: 117-123

Die Behandlungen des chronischen Coma hepaticum mit Laktulose  
*Therapeutische Umschau und medizinische Bibliographie*, 1969, 26: 275-277

Lactulose treatment of chronic hepatportal encephalopathy: a clinical and electroencephalographic study  
*Acta medica Scandinavica*, 1970, 187: 337-346

The value of EEG frequency analysis in hepatic encephalopathy  
*J. Ryl. Coll. Surg. Edinb.*, 1970, 15: 151-157

Some observations on the effects of treatment with lactulose on patients with chronic hepatic encephalopathy  
*Quarterly Journal of Medicine*, 1970, 39: 245-263

A controlled clinical trial of lactulose in hepatic encephalopathy  
*Gastroenterology*, 1970, 59: 827-832

Duphalac syrup is supplied in bottles of 200 ml and 2 litres. It contains lactulose 50% w/w, galactose 8% w/w and lactose 5% w/w.

Further information available on request.

**duphar**

DUPHAR LABORATORIES LIMITED WEST END SOUTHAMPTON TEL 04218 2281  
PHILIPS-DUPHAR (IRELAND) LIMITED RAINSFORD STREET DUBLIN 8 TEL DUBLIN 754271



# GASTROENTEROLOGY:

## The monthly seminar

You may object to our calling a medical journal a seminar. But consider it this way: each month, you share in the results of research and clinical studies of your confreres. When the after-hours free you at the end of the day's appointments, consult GASTROENTEROLOGY. You'll find:

- 1.) **Selected summaries.** Abstracts of relevant new work, with a brief expert critique.
- 2.) **Original papers.** Studies of the liver, alimentary tract, pancreas and biliary tract.
- 3.) **Case Studies.** Dealing with clinical research.

Too, there'll be editorials, symposium reports, and a "special comments" section for readers to present their views of papers that have appeared in recent issues—your chance to participate in the "monthly seminar" when you so desire.

*GASTROENTEROLOGY.* The official organ of the American Gastroenterological Association. From the Williams and Wilkins Company.

Published monthly/2 volumes per year/Subscription: \$25 (Resident rate: \$15.00)  
Overseas postage: \$3.00

### Sample Selections

**Presentation of the Julius Friedenwald Medal to Andrew Conway Ivy.**  
*M. I. Grossman*

**Effect of Long Term Anticholinergic Therapy on Gastric Acid Secretion, with Observations on the Serial Measurement of Peak Histalog Response.**  
*R. P. Norgaard, D. E. Polter, J. W. Wheeler, Jr., and J. S. Fordtran.*

**A Controlled Study on the Use of Propantheline and Amylopectin Sulfate (SN-263) for Recurrences in Duodenal Ulcer.** *D. C. H. Sun and M. L. Ryan.*

**Basal and Histamine-stimulated Human Gastric Acid Secretion. Lack of Effect of Indomethacin in Therapeutic Doses.** *D. H. Winship and G. C. Bernhard.*

**Gastric Juice Lactic Acidosis in the Presence of Gastric Carcinoma.** *D. W. Piper, M. L. Kemp, B. H. Fenton, M. J. Croydon, and A. D. Clarke.*

Published by **The Williams & Wilkins Company, Baltimore, Maryland, U.S.A.**

Sole agent in England: **Bailliere, Tindall & Cassell Ltd., 7 & 8 Henrietta Street, Covent Garden, London, W.C.2**